In CRSwNP, mepolizumab effectively suppresses IL-5-mediated eosinophil activation, yet persistent IL-33/TSLP signaling in local microenvironments may drive residual inflammation, leading to partial therapeutic responses. This evidence concerns the gene TSLP and chronic rhinosinusitis with nasal polyps.